3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Multiple Myeloma
4
Lymphoma
4
Hodgkin Disease
4
Breast Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Hematologic Neoplasms
3
Vomiting
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma in Situ
2
Burkitt Lymphoma
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Interventions
Cisplatin
136
Radiotherapy
90
Cetuximab
89
pembrolizumab
65
Fluorouracil
56
Docetaxel
56
Carboplatin
51
Paclitaxel
44
Radiotherapy, Intensity-Modulated
37
Nivolumab
35
durvalumab
19
Erlotinib Hydrochloride
18
Immunohistochemistry
16
Radiation
13
tremelimumab
12
Gemcitabine
11
Surgical Procedures, Operative
10
Gene Expression Profiling
10
Drug Therapy
10
Biopsy
10
Albumin-Bound Paclitaxel
10
Chemotherapy, Adjuvant
9
Capecitabine
9
Bevacizumab
9
atezolizumab
8
Radiosurgery
8
Polymerase Chain Reaction
8
Neoadjuvant Therapy
8
Ipilimumab
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Squamous Cell Carcinoma of Head and Neck
×
Diphenhydramine
×
Clear all
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts